Why the study?
Venous thromboembolism is a leading cardiovascular cause of maternal morbidity and mortality, but optimal management of pregnancy-related VTE requires further evaluation.
Does subtherapeutic dosing of LMWH after an initial intensive period prevent recurrent VTE in pregnant women with acute VTE?
Observational (n=201)
Yes
Does subtherapeutic dosing of LMWH after an initial intensive period prevent recurrent VTE in pregnant women with acute VTE?
Answers are grounded in this paper and cite their sources.
In pregnant women with acute VTE, reducing the LMWH dose by 25-50% after 1-2 weeks of intensive treatment resulted in very low rates of recurrent VTE and major bleeding, suggesting a potential alternative to uninterrupted full-dose therapy.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Prandoni et al. (2022) conducted an observational in Pregnancy-related venous thromboembolism (n=201). Low-molecular-weight heparin (LMWH) was evaluated on Objectively confirmed recurrent venous thromboembolism.
Synapse has enriched 10 related papers. Consider them for comparative context: